IDH1 and glioblastoma: Although, LGGs have lower incidence rate and malignancy compared with glioblastoma (GBM), IDH-wildtype(CNS WHO grade 4), it also causes considerable mortality and presents a therapeutic challenge due to the heterogeneity of their clinicopathological features [4, 5].